Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $270.00 at HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA) had its price target lifted by equities researchers at HC Wainwright from $255.00 to $270.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 134.25% from the stock’s current price.

A number of other equities research analysts have also issued reports on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th. Stifel Nicolaus set a $250.00 price target on Palvella Therapeutics in a research note on Tuesday, February 24th. Craig Hallum assumed coverage on Palvella Therapeutics in a report on Thursday, December 4th. They issued a “buy” rating and a $175.00 price objective for the company. Truist Financial set a $210.00 price objective on Palvella Therapeutics in a research note on Tuesday, February 24th. Finally, UBS Group reaffirmed a “buy” rating and set a $143.00 target price on shares of Palvella Therapeutics in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $185.87.

Palvella Therapeutics Price Performance

PVLA traded down $1.78 during trading on Tuesday, hitting $115.26. The company had a trading volume of 49,541 shares, compared to its average volume of 311,983. Palvella Therapeutics has a 1-year low of $18.23 and a 1-year high of $151.18. The company has a market cap of $1.36 billion, a PE ratio of -44.00 and a beta of -0.31. The business has a 50-day moving average of $103.44 and a 200-day moving average of $89.12.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Elaine J. Heron acquired 2,400 shares of Palvella Therapeutics stock in a transaction dated Friday, February 27th. The shares were acquired at an average price of $125.00 per share, with a total value of $300,000.00. Following the completion of the transaction, the director owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. This trade represents a 5.28% increase in their position. The SEC filing for this purchase provides additional information. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Palvella Therapeutics

Several large investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC acquired a new stake in shares of Palvella Therapeutics in the third quarter valued at $33,949,000. Summit Partners Public Asset Management LLC grew its holdings in Palvella Therapeutics by 1,016.0% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after acquiring an additional 354,525 shares during the period. Federated Hermes Inc. acquired a new position in Palvella Therapeutics during the third quarter worth about $21,255,000. Vanguard Group Inc. raised its position in Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after acquiring an additional 330,847 shares in the last quarter. Finally, State Street Corp raised its position in Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after acquiring an additional 283,211 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.